Apogee is seeking to reshape the current standard of care for inflammatory and immune diseases because we believe people living with these diseases deserve the best possible treatment.
Our pipeline of differentiated antibody therapeutics targets well-established biological drivers and development pathways, with an initial focus on making impactful advancements in the treatment of atopic dermatitis and chronic obstructive pulmonary disease.
People first, always